Show simple item record

dc.contributor.authorEndy, Timothy P.
dc.contributor.authorNisalak, Ananda
dc.contributor.authorChunsuttitwat, Supamit
dc.contributor.authorVaughn, David W.
dc.contributor.authorGreen, Sharone
dc.contributor.authorEnnis, Francis A.
dc.contributor.authorRothman, Alan L.
dc.contributor.authorLibraty, Daniel H.
dc.date2022-08-11T08:09:09.000
dc.date.accessioned2022-08-23T16:19:28Z
dc.date.available2022-08-23T16:19:28Z
dc.date.issued2004-03-15
dc.date.submitted2017-08-22
dc.identifier.citationJ Infect Dis. 2004 Mar 15;189(6):990-1000. Epub 2004 Mar 1. doi:10.1086/382280. <a href="https://doi.org/10.1086/382280">Link to article on publisher's site</a>
dc.identifier.issn0022-1899 (Linking)
dc.identifier.doi10.1086/382280
dc.identifier.pmid14999601
dc.identifier.urihttp://hdl.handle.net/20.500.14038/35054
dc.description.abstractBACKGROUND: Infection with any 1 of the 4 dengue viruses (DVs) can produce several illnesses, ranging from a mild febrile illness to classic dengue fever (DF) to dengue hemorrhagic fever (DHF), a potentially life-threatening disease. Most DHF cases occur after sequential heterotypic DV infections. The role of preexisting humoral immunity in modifying severity of dengue disease is not well understood. METHODS: We conducted a prospective cohort study of children in a region where dengue disease is hyperendemic and examined the role of preexisting neutralizing anti-DV antibodies (Abs) in modifying secondary dengue-3 virus (D3V), dengue-2 virus (D2V), and dengue-1 virus (D1V) infections. RESULTS: In secondary D3V infection, higher levels of preexisting neutralizing Ab directed against D3V (reference virus strain and patient's virus isolate) were associated with lower viremia levels and milder disease. Preexisting neutralizing Ab levels against D2V were not associated with severity of secondary D2V infection. The levels of preexisting neutralizing Ab against the infecting virus isolates were not associated with viremia levels in secondary D2V or D1V infections. CONCLUSIONS: Cross-reactive memory humoral immune responses appear to be beneficial in symptomatic secondary D3V infection, but not in secondary D2V or D1V infection. These results may have important implications for the development of live attenuated tetravalent dengue vaccines.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=14999601&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://doi.org/10.1086/382280
dc.subjectImmunity
dc.subjectImmunology and Infectious Disease
dc.subjectImmunology of Infectious Disease
dc.subjectInfectious Disease
dc.titleRelationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand
dc.typeJournal Article
dc.source.journaltitleThe Journal of infectious diseases
dc.source.volume189
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/infdis_pp/268
dc.identifier.contextkey10636644
html.description.abstract<p>BACKGROUND: Infection with any 1 of the 4 dengue viruses (DVs) can produce several illnesses, ranging from a mild febrile illness to classic dengue fever (DF) to dengue hemorrhagic fever (DHF), a potentially life-threatening disease. Most DHF cases occur after sequential heterotypic DV infections. The role of preexisting humoral immunity in modifying severity of dengue disease is not well understood.</p> <p>METHODS: We conducted a prospective cohort study of children in a region where dengue disease is hyperendemic and examined the role of preexisting neutralizing anti-DV antibodies (Abs) in modifying secondary dengue-3 virus (D3V), dengue-2 virus (D2V), and dengue-1 virus (D1V) infections.</p> <p>RESULTS: In secondary D3V infection, higher levels of preexisting neutralizing Ab directed against D3V (reference virus strain and patient's virus isolate) were associated with lower viremia levels and milder disease. Preexisting neutralizing Ab levels against D2V were not associated with severity of secondary D2V infection. The levels of preexisting neutralizing Ab against the infecting virus isolates were not associated with viremia levels in secondary D2V or D1V infections.</p> <p>CONCLUSIONS: Cross-reactive memory humoral immune responses appear to be beneficial in symptomatic secondary D3V infection, but not in secondary D2V or D1V infection. These results may have important implications for the development of live attenuated tetravalent dengue vaccines.</p>
dc.identifier.submissionpathinfdis_pp/268
dc.contributor.departmentCenter for Infectious Disease and Vaccine Research
dc.contributor.departmentDepartment of Medicine, Division of Infectious Diseases and Immunology
dc.source.pages990-1000


This item appears in the following Collection(s)

Show simple item record